Influence of homocysteine on the function of native arteriovenous fistula in hemodialysis patients

Dialysis and Transplantation

Volumn 35, Issue 10, 2006, Pages 604-609

  Bednarek Skublewska, Anna ^a   Przywara, Stanislaw ^a   Wroński, Jacek ^a   Ksia̧zek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ANASTOMOSIS; ARTERIOVENOUS FISTULA; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; INCIDENCE; INTERVENTION STUDY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NUTRITIONAL STATUS; OSTEODYSTROPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RETROSPECTIVE STUDY; STENOSIS; THROMBOSIS; TREATMENT DURATION;

EID: 54549103369     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: 10.1002/dat.20044     Document Type: Article

References (25)

1. Leapman SB, Boyle M, Pescovitz MD, et al. The arteriovenous fistula for hemodialyssis access: Gold standard or archaic relict? Am Surg. 1996;62:652-656.
2. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 2001;60:1443-1451.
3. Dixon BS, Novak L, Fangaman J. Hemodialysis vascular access survival: upperarm native arteriovenous fistula. Am J Kidney Dis. 2002;39:92-101.
4. Graham IM, Daly LE, Refsum HM. Plasma homocysteine as a risk factor for vascular disease. The European Concreated Action Project. JAMA. 1997;277:1775-1781.
5. Bostom AG, Shemin D, Lapane Kl. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end stage renal disease patients: a case control study. Atherosclerosis. 1995;114:93-103.
6. Bostom AG, Shemin D, Verhoef P. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554-2558.
7. Mallamaci F, Bonanno G, Seminara G, et al. Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis. 2005;45:702-707.
8. Massy ZA. Hyperhomocysteinaemia in renal failure- what are the implementations? Nephrol Dial Transplant. 1996;11:2392-2393.
9. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease. Prevalence, ethiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997;52:10-20.
10. Bostom AG, Shemin D, Lapane Kl. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end stage renal disease patients: a case control study. Atherosclerosis. 1995;114:93-103.
11. Shemin D, Lapane Kl, Bausserman L, et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol. 1999,10;1096-1099.
12. Bachmann I, Tepel M, Raidt H. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995;6:121-125.
13. Bowden RG, Wyatt FB, Wilson R, Wilborn C, Gentile M. Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren Fail. 2004;2:709-714.
14. Hojs R, Gorenjak M, Ekart R, Dvorsak B, Pecovnik-Balon B. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail. 2002;24:215-22.
15. NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis. 2001;37:7-64.
16. K/DOQI, National Kidney Foundation 2000. Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000; 35:1-40.
17. Suliman ME, Barany P, Kalanantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia- a puzzling and conflicting story. Nephrol Dial Transplant. 2004;20:16-21.
18. Fukasawa M, Matsushita K, Kamiyama M, et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis. 2003;41:637-642.
19. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407-413.
20. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1993;77:1370-1376.
21. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia, anticardiovascular outcomes in hemodialysis patients. Kidney Int. 2002;61:609-614.
22. Nakhoul F, Abassi Z, Plawner M, et al. Comparative study of response to treatment with supraphysiologic doses of B-vitamin in hyperhomocysteinemic hemodialysis patients. Isr Med Assoc J. 2004;6:213-217.
23. Manus BJ, Burgess ED, Parsons HG, Scharfer JP, Hyndaman ME, Scott-Douglas NM. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int. 1999,55:315-320.
24. Sirrs S, Duncan L, Djurdjev O, et al. Homocysteine and vascular access complications in haemodialysis pateints: insights into a complex metabolic relationship. Nephrol Dial Transplant. 1999;14:738-743.
25. Grandaliano G, Teutonico A, Allegretti A, Losappio R, Mancisi A, Gesualdo L. The role of hyperparathyroidism, erythropoietin therapy and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney Int. 2003;62:715-719.